Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Distribution and Antifungal Susceptibilities of Candida Species Isolated from Blood Cultures from 2016 to 2023 years

  • Seung Bok Hong (Department of Clinical Laboratory Science, Chungbuk Health & Science University)
  • Received : 2024.05.03
  • Accepted : 2024.05.31
  • Published : 2024.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The aim of this study was to investigate the distribution and antifungal susceptibilities of Candida spp. from blood culture to provide useful information on empirical treatment of Candidemia. We investigated distribution and antifungal susceptibilities of Candida spp. isolated from blood culture during an 8-years (2016-2023) in a C-University hospital. Over 8 years, 1,182 Candida strains from blood culture were isolated, which was fourth most common cause of bloodstream infection. Among nonduplicated 350 Candida strains, C. albicans was the most common with 45.43%, followed by C. glabrata (17.43%), C. tropicalis (17.43%), C. parapsilosis (14.86%), C. guilliermondii (1.71%), C. krusei (0.86%), C. lusitaniae (0.86%), C. ciferrii (0.57%). In the antifungal susceptibility testing on 323 Candida strains, the non-susceptibility rate was 2.48% for amphotericin B, 1,71% for flucytosine, 3.09% for fluconazole, 4.66% for voriconazole, 5.57% for caspofungin, and 0.62% for micafungin. In particular, C. albicans showed non-susceptibility of 8.23% to voriconazole, and C. glabrata showed 14.81% and 24.59% to fluconazole and caspofungin, respectively. These data showed that the prevalence of candidemia is very common, and antifungal resistance in Candida spp., especially C. glabrata, is increasing. Therefore, periodic surveillance of prevalence and antifungal susceptibility of blood culture is very important for clinical laboratory.

Keywords

References

  1. Al-Dorzi HM, Sakkijha H, Khan R, Aldabbagh T, Toledo A, Ntinika P, et al. Invasive Candidiasis in critically ill patients: a prospective cohort study in two tertiary care centers. J Intensive Care Med. 2020. 35: 542-553.
  2. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013. 56: 1724-1732.
  3. Bassetti M, Peghin M, Timsit JF. The Current Treatment Landscape: Candidiasis. J Antimicrob Chemother. 2016. 71: ii13-ii22.
  4. Boonyasiri A, Jearanaisilavong J, Assanasen S. Candidemia in Siriraj hospital: epidemiology and factors associated with mortality. J Med Assoc Thai. 2013. 96: S91-S97.
  5. Castanheira M, Messer SA, Rhomberg PR, Pfaller MA. Antifungal susceptibility patterns of a global collection of fungal isolates: Results of the SENTRY antifungal surveillance program (2013). Diagn Microbiol Infect Dis. 2016. 85: 200-204.
  6. Chen PY, Chuang YC, Wang JT, Sheng WH, Yu CJ, Chu CC, et al. Comparison of epidemiology and treatment outcome of patients with candidemia at a teaching hospital in Northern Taiwan, in 2002 and 2010. J Microbiol Immunol Infect. 2012. 47: 95-103.
  7. CLSI. Performance standards for antifungal susceptibility testing of yeast, 1st ed; CLSI supplement M60; Clinical and Laboratory Standard Institute: Wayne, PA, USA, 2017.
  8. da Matta DA, Souza ACR, Colombo AL. Revisiting Species Distribution and Antifungal Susceptibility of Candida Bloodstream Isolates from Latin American Medical Centers. J Fungi. 2017. 3: 24.
  9. Das I, Nightingale P, Patel M, Jumaa P. Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int J Infect Dis. 2011. 15: e759-e763.
  10. Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014. 20 (Suppl. S6): 5-10.
  11. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009. 48: 1695-1703.
  12. Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis. 1999. 29: 1164-1170.
  13. Kim JH, Suh JW, Kim MJ. Epidemiological trends of candidemia and the impact of adherence to the candidemia guideline: Six-year single-center experience. J Fungi. 2021. 7: 275.
  14. Kothari A, Sagar V. Epidemiology of Candida bloodstream infections in a tertiary care institute in India. Indian J Med Microbiol. 2009. 27: 171-172.
  15. Kwon YJ, Won EJ, Jeong SH, Shin KS, Shin JH, Kim YR, et al. Dynamics and predictors of mortality due to candidemia caused by different Candida species: comparison of intensive care unit-associated candidemia (ICUAC) and non-ICUAC. J Fungi. 2021. 7: 597.
  16. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015. 373: 1445-1456.
  17. Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018. 73: i4-i13.
  18. Lim HJ, Shin JH, Kim MN, Yong D, Byun SA, Choi MJ, et al. Evaluation of two commercial broth microdilution methods using different interpretive criteria for the detection of molecular mechanisms of acquired azole and echinocandin resistance in four common Candida species. Antimicrob Agents Chemother. 2020. 64: e00740-20.
  19. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: A prospective multicenter study involving 2441 patients. Antimicrob Agents Chemother. 2011. 55: 532-538.
  20. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016. 62: e1-e50.
  21. Pema'n J, Canto'n E, Quindo's G, Eraso E, Alcoba J, Guinea J, et al. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother. 2012. 67: 1181-1187.
  22. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol. 2001. 39: 3254-3259.
  23. Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty Years of the SENTRY Antifungal Surveillance Program: results for Candida species from 1997-2016. Open Forum Infect Dis. 2019. 6: S79-S94.
  24. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: Comparison of species distributions and antifungal resistance patterns in communityonset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother. 2011. 55: 561-566.
  25. Pfaller MA, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. Epidemiology and outcomes of candidemia in 3648 patients: data from the prospective antifungal therapy (PATH Alliance®) registry, 2004-2008. Diag Microbiol Infect Dis. 2012. 74: 323-331.
  26. Tai-Aldeen SJ, Kolecka A, Boesten R, Alolaqi A, Almaslamani M, Chandra P, et al. Epidemiology of candidemia in Qatar, the middle east: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern. Infection. 2014. 42: 393-404.
  27. Tan TY, Hsu LY, Alejandria MM, Chaiwarith R, Chinniah T, Chayakulkeeree M, et al. Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region. Med Mycol. 2016. 54: 471-477.
  28. Tan BH, Chakrabarti A, Li RY, Patel AK, Watcharananan SP, Liu Z, et al. Incidence and species distribution of candidemia in Asia: A laboratory-based surveillance study. Clin Microbiol Infect. 2015. 21: 946-953.
  29. Tortorano AM, Prigitano A, Lazzarini C, Passera M, Deiana ML, Cavinato S, et al. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection. 2013. 41: 655-662.
  30. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. National nosocomial infections surveillance system hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis. 2002. 35: 627-630.
  31. Won EJ, Choi MJ, Kim MN, Yong D, Lee WG, Uh Y, et al. Fluconazole-resistant Candida glabrata bloodstream isolates, South Korea, 2008-2018. Emerg Infect Dis. 2021. 27: 779-788.
  32. Won EJ, Choi MJ, Jeong SH, Kim D, Shin KS, Shin JW, et al. Nationwide surveillance of antifungal resistance of Candida bloodstream isolates in South Korean hospitals: two years report from Kor-GLASS. J Fungi. 2022. 8: 996.
  33. Zhang XB, Yu SJ, Yu JX, Gong YL, Feng W, Sun FJ. Retrospective analysis of epidemiology and prognostic factors for candidemia at a hospital in China, 2000-2009. Jpn J Infect Dis. 2012. 65: 510-515.